RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-MASKED STUDY OF THE SAFETY AND EFFICACY OF POS (0.75% PHENTOLAMINE OPHTHALMIC SOLUTION) IN PARTICIPANTS WITH PREVIOUS KERATOREFRACTIVE SURGERY WITH DECREASED VISUAL ACUITY UNDER MESOPIC CONDITIONS
Latest Information Update: 11 Sep 2026
At a glance
- Drugs Phentolamine (Primary)
- Indications Nyctalopia
- Focus Registrational; Therapeutic Use
- Acronyms LYNX-3
- Sponsors Ocuphire Pharma
Most Recent Events
- 08 Sep 2026 Planned number of patients changed from 200 to 580.
- 08 Sep 2026 Planned End Date changed from 1 Jun 2026 to 1 Aug 2027.
- 08 Sep 2026 Planned primary completion date changed from 1 Jun 2026 to 1 Aug 2027.